Here in the U.S. we just had our big Thanksgiving holiday, but science goes, stem cells keep growing and needing attention, and it’s another weekend chance to catch up on our paper reading. Here’s this weekend edition of recommended reads including news items and pubs. From Cell Stem Cell: Single-Cell Transcriptome Analysis of Uniparental Embryos Reveals […]
The FDA just sent another untitled letter to a producer of a potentially non-compliant perinatal “stem cell” product that may be an unapproved drug. This follows past non-warning letters and/or inspection reports made public to Liveyon, R3 Stem Cell, Stemell, and others. RAPS has more on the story of the new letter here. This newest
Another FDA letter to a stem cell clinic supplier: what’s the agency’s long game? Read More »
I finished listening to the first 6 episodes of the Bad Batch podcast last week. The series is by medical journalist Laura Beil. I think there will be a 7th episode that’s a Q&A. I highly recommend listening to the series even if parts are wrenching at times like how much patients and families have
Bad Batch podcast’s dark picture of perinatal stem cell industry Read More »
The stem cell universe is populated by sometimes mysterious acronyms (see an image of a whole alphabet stem cell acronym soup), many of which refer to specific kinds of stem cells including one nebulous type called MUSE cells. MUSE cells clinical trials I’m not convinced that MUSE cells exist, but oddly there appear to be
MUSE cells are in 4 Japanese stem cell trials despite doubts Read More »
Back in May, the FDA cautioned a stem cell clinic firm called R3 Stem Cell and its leader David Greene about what they were doing. Importantly, the agency indicated that some of R3’s stem cells may be unapproved drug products. FDA and R3 Stem Cell While the FDA didn’t send R3 Stem Cell a formal warning
I’ve been concerned about a stem cell group called MD Stem Cells for many years. Now it comes under more scrutiny from a new must-read piece by Donna Young over at S&P Global. Young’s article reports a puzzling, purported right-to-try (RTT) program that MD Stem Cells appears to working on with Richard Garr. Note that
MD Stem Cells purported Right To Try program Read More »
I’m relatively new to podcasts, but am enjoying a new stem cell-focused one called Bad Batch by medical journalist Laura Beil, which I’ve been listening to in the car as I commute. I just finished episode three. I’m curious to hear how the next few episodes of the story unfold. I talked and emailed with
Bad Batch podcast is must listen for stem cell community Read More »
When it comes to coverage of stem cell research in the media, science news can both be cool, but also surprising. Some of the more interesting publications don’t always draw news coverage too. This post is a list of recent notable pubs and news. First some pubs. How good are human brain organoids at modeling
Recommended reads: stem cell pubs plus science news Read More »
Over the years I’ve asked patients to talk about their experiences getting a stem cell therapy. One particular post in 2016 has drawn almost 400 comments, many from patients. The insights provided by these patients and the questions asked in the comment stream have provided a unique window into what’s going on out there. There
If you’ve had a stem cell therapy, how was your experience? Read More »
As of October 1, Google was supposed to have banned ads for unproven stem cell clinics and products. This was according to their own new policy. How’s that going? How’s this new Google approach to unproven stem cell marketing working out in the real wild world of the web? To test it, I did over
My B grade to Google on early test of its stem cell clinic ad ban Read More »